Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study

References

• Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–1231.
   PubMed Web of Science ®Google Scholar
• Mohr BA, Bhasin S, Link CL, et al. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol. 2006;155(3):443–452.
   PubMed Web of Science ®Google Scholar
• Derby CA, Zilber S, Brambilla D, et al. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2006;65(1):125–131.
   PubMed Web of Science ®Google Scholar
• Kawano H. The relationship between testosterone and metabolic syndrome. Hypertens Res. 2010;33(6):537–538.
   PubMed Web of Science ®Google Scholar
• Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2(6):335–348.
   PubMedGoogle Scholar
• Medina J, Fernández-Salazar LI, García-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27(8):2057–2066.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology. 2007;46(5):1387–1391.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–944.
   PubMed Web of Science ®Google Scholar
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112.
   PubMed Web of Science ®Google Scholar
• Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–161.
   PubMed Web of Science ®Google Scholar
• Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–350.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006;23(4):403–409.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541–3546.
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30(8):2119–2121.
   PubMed Web of Science ®Google Scholar
• Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350.
   PubMed Web of Science ®Google Scholar
• Wójcik-Cichy K, Koślińska-Berkan E, Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol. 2018;4(1):1–6.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin AA, Nettleship JE, et al. Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Arab J Urol. 2016;14(1):31–36.
   PubMed Web of Science ®Google Scholar
• Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496–503.
   PubMed Web of Science ®Google Scholar
• Jones TH. Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010;2(3):146–156.
   PubMed Web of Science ®Google Scholar
• Traish AM, Guay A, Feeley R, et al. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl. 2009;30(1):10–22.
   PubMed Web of Science ®Google Scholar
• Daka B, Langer RD, Larsson CA, et al. Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disord. 2015;15:35–35.
   PubMed Web of Science ®Google Scholar
• Hackett G. Type 2 diabetes and testosterone therapy. World J Mens Health. 2019;37(1):31–44.
   PubMedGoogle Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The Aging Male. 2003;6(1):1–7.
   PubMedGoogle Scholar
• Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733.
   PubMedGoogle Scholar
• Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010;142(1):50–55.
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73(5):602–612.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM; TIMES2 Investigators, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–837.
   PubMed Web of Science ®Google Scholar
• Völzke H, Aumann N, Krebs A, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl. 2010;33(1):45–53.
   PubMedGoogle Scholar
• Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69.
   PubMed Web of Science ®Google Scholar
• Barbonetti A, Caterina Vassallo MR, Cotugno M, et al. Low testosterone and non-alcoholic fatty liver disease: evidence for their independent association in men with chronic spinal cord injury. J Spinal Cord Med. 2016;39(4):443–449.
   PubMed Web of Science ®Google Scholar
• Kley HK, Nieschlag E, Wiegelmann W, et al. Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis. Acta Endocrinol (Copenh). 1975;79(2):275–285.
   PubMedGoogle Scholar
• Myking O, Aakvaag A, Digranes Ø. Androgen-oestrogen imbalance in men with chronic alcoholism and fatty liver. Alcohol Alcohol. 1987;22(1):7–15.
   PubMed Web of Science ®Google Scholar
• Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167(4):531–541.
   PubMed Web of Science ®Google Scholar
• Senmaru T, Fukui M, Okada H, et al. Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet. Metabolism. 2013;62(6):851–860.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Nettleship JE, Akhtar S, et al. Testosterone suppresses the expression of regulatory enzymes of fatty acid synthesis and protects against hepatic steatosis in cholesterol-fed androgen deficient mice. Life Sci. 2014;109(2):95–103.
   PubMed Web of Science ®Google Scholar
• Nikolaenko L, Jia Y, Wang C, et al. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology. 2014;155(2):417–428.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yee JK, Wang C, et al. Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. Am J Physiol Endocrinol Metab. 2018;314(4):E366–E376.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):R25–45.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.
   PubMed Web of Science ®Google Scholar
• Boden WE, Miller MG, McBride R, et al. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020;224:65–76.
   PubMed Web of Science ®Google Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–1675.
   PubMed Web of Science ®Google Scholar
• Morgunov LY, Denisova IA, Rozhkova TI, et al. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male. 2020;23(1):71–80.
   PubMed Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. The Aging Male. 2018;21(3):158–169.
   PubMed Web of Science ®Google Scholar
• Salman M, Yassin DJ, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. The Aging Male. 2017;20(1):45–48.
   PubMed Web of Science ®Google Scholar
• Canguven O, Talib RA, El Ansari W, et al. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men. Andrologia. 2017;49(10):e12768.
   Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond). 2016;40(1):162–170.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Nettleship J, Almehmadi Y, et al. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. Andrologia. 2016;48(7):793–799.
   PubMed Web of Science ®Google Scholar
• Magnussen LV, Andersen PE, Diaz A, et al. MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial. Eur J Endocrinol. 2017;177(2):157–168.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Dia Care. 2016;39(1):82–91.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102(12):2708–2715.
   PubMed Web of Science ®Google Scholar
• Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581–606.
   PubMed Web of Science ®Google Scholar
• Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47(6):1924–1935.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Hopkins LJ, Reynolds GM, et al. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154(12):4536–4547.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Akhtar S, Sellers DJ, et al. Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse. Endocrine. 2016;54(2):504–515.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu Y, Wang L, et al. Differential effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res. 2013;54(2):345–357.
   PubMed Web of Science ®Google Scholar
• Westerbacka J, Cornér A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47(8):1360–1369.
   PubMed Web of Science ®Google Scholar
• Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112(14):2078–2080.
   PubMed Web of Science ®Google Scholar
• Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13(1):36–41.
   PubMedGoogle Scholar
• Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. Ann Transl Med. 2016;4(24):481–481.
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. ATVB. 2007;27(1):127–133.
   Google Scholar
• Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314–329.
   PubMed Web of Science ®Google Scholar
• Weng SF, Kai J, Guha IN, et al. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart. 2015;2(1):e000272
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Watanabe T, Otaki Y, et al. Association of the aspartate aminotransferase to alanine aminotransferase ratio with BNP level and cardiovascular mortality in the general population: the yamagata study 10-year follow-up. Dis Markers. 2016;2016:4857917.
   PubMed Web of Science ®Google Scholar
• Choi KM, Han K, Park S, et al. Implication of liver enzymes on incident cardiovascular diseases and mortality: a nationwide population-based cohort study. Sci Rep. 2018;8(1):3764–3764.
   PubMed Web of Science ®Google Scholar
• Wallis CJ, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes & Endocrinol. 2016;4(6):498–506.
   PubMed Web of Science ®Google Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327.
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Alwani M, et al. Long-term testosterone therapy improves renal function in men with hypogonadism: a real-life prospective controlled registry. J Clin Nephrol Res. 2020;7(1):1095.
   Google Scholar
• Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports. Aging Male. 2015;18(3):164–168.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64–69.
   PubMed Web of Science ®Google Scholar